SCHEMBL13720913

SCHEMBL13720913

CC(C)(C)N(Cc1nn(NC(=O)CC2CCCCC2)c(=O)c2ccccc12)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ LMNA P02545 3/20 0.43
▸ HTT P42858 3/20 0.43
▸ TSHR P16473 1/20 0.43
▸ ALPL P05186 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ EPHX2 P34913 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ MEN1 O00255 2/20 0.38
▸ HRH1 P35367 1/20 0.38
▸ HRH3 Q9Y5N1 1/20 0.38
▸ KCNQ3 O43525 1/20 0.38
▸ KCNQ2 O43526 1/20 0.38
▸ P2RX7 Q99572 2/20 0.37
▸ GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13720752 0.89 CHRNA7 (0.37) ALDH1A1KMT2ASMN1; SMN2LMNAHTT
SCHEMBL13720349 0.83 HPGD (0.37) ALDH1A1KMT2ASMN1; SMN2LMNAHTT
SCHEMBL13721202 0.81 OGFRL1 (0.39) ALDH1A1SMN1; SMN2LMNAHTTTSHR
SCHEMBL13721204 0.81 OGFRL1 (0.39) ALDH1A1SMN1; SMN2LMNAHTTTSHR
SCHEMBL16155933 0.80 RAB9A (0.51) ALDH1A1KMT2ASMN1; SMN2LMNAHTT
SCHEMBL13721432 0.79 LMNA (0.50) KMT2ASMN1; SMN2LMNAKDM4E
SCHEMBL13720957 0.79 SMN1; SMN2 (0.47) ALDH1A1KMT2ASMN1; SMN2LMNAHTT
SCHEMBL13721811 0.79 KDM4E (0.46) ALDH1A1KMT2ALMNAHTTL3MBTL1
SCHEMBL1786371 0.78 ALDH1A1 (0.50) ALDH1A1KMT2ASMN1; SMN2LMNAHTT
SCHEMBL30795801 0.78 ALDH1A1 (0.50) ALDH1A1KMT2ASMN1; SMN2LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120289500-A1 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2012-11-15 — — US claimed
US-8859549-B2 Potassium channel modulators ABBVIE, INC. (US) 2014-10-14 — — US disclosed
WO-2012158399-A1 CONDENSED 2 - CARBAMOYLPYRIDAZINONES AS POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2012-11-22 — — WO disclosed
US-20120289500-A1 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2012-11-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289500-A1 POTASSIUM CHANNEL MODULATORS KCNQ1, KCNQ2, KCNJ2 ALDH1A1 743/4885KMT2A 574/4885SMN1; SMN2 1602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback